Pharmacokinetics and safety review of tazarotene - 09/09/11
Abstract |
The safety profile of tazarotene is superior to that of orally administered retinoids. The limited percutaneous penetration of tazarotene limits its systemic absorption and this, combined with its rapid metabolism in the skin and the plasma to the more water-soluble active metabolite, tazarotenic acid, helps prevent accumulation of the drug in fat containing tissues. Urinary and fecal elimination are virtually complete within 2 to 3 days and 7 days after dosing, respectively. Tazarotene also exhibits no indication of mutagenicity, carcinogenicity, phototoxic potential, photoallergic potential, or contact sensitization. (J Am Acad Dermatol 1998;39:S134-8.)
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by Allergan Skin Care. |
| Reprint requests: Professor R. Marks, Head, Department of Dermatology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, U.K. |
 | 0190-9622/98/$5.00 + 0 16/0/92888 |
Vol 39 - N° 4S
P. S134-S138 - octobre 1998 Retour au numéro
Article précédent
- The pathogenesis of psoriasis and the mechanism of action of tazarotene
- Madeleine Duvic, Arisa T. Asano, Carina Hager, Steven Mays
- Tazarotene in combination with topical corticosteroids
- Mark Lebwohl, Yves Poulin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?